Investor Presentation and Strategy Update
Filed with ASX · · 24 pages · English
BRISBANE, 18th July 2018: Anatara Lifesciences (ASX:ANR) is pleased to release its latest presentation and strategy update that will be delivered to institutional investors this week. In outlining its future strategy, Anatara has provided an update on its efforts to develop its product pipeline, extending from its core application to control diarrhoea in pigs, to the management of human gastrointe
Anatara Lifesciences Ltd on 6ix
In the deck
Earlier from Anatara Lifesciences
- Anatara CEO announces retirement
- Exclusive Global License Agreement with Zoetis
- FDA approves the Human Food Safety Dossier
- R&D Tax Incentive Received
- Pork CRC Options extended by 12 Months
Later from Anatara Lifesciences
- Appendix 4E & Audited Financial Statements
- APVMA approval for Detach
- Chief Executive Officer Appointment
- R&D Tax Refund Received
- Successful proof of concept studies
Follow Anatara Lifesciences into a list and get an email when it puts out news.
Follow Anatara Lifesciences